- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05745038
A Single Arm Pilot Trial of a Social Network Intervention (SONATA)
March 5, 2024 updated by: Kah Poh Loh, University of Rochester
A Single Arm Pilot Trial of a Social Network Intervention (SONATA) for Older Patients on Oral Anticancer Treatments and Their Network Members
The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust & Adherence or SONATA) is helpful for older individuals receiving cancer treatment.
The SONATA program will last for about 4 months.
There are a total of 6 coaching sessions.
The first 5 sessions will be held approximately every 1 to 2 weeks.
Session 6 or the final session will be held approximately 1 to 2 months after session 5.
Each session will last for about 1 to 2 hours.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lauren Mitchell
- Phone Number: 585-275-1192
- Email: Lauren_Mitchell@URMC.rochester.edu
Study Contact Backup
- Name: Kah Poh Loh
- Phone Number: 585-276-4353
- Email: Kahpoh_Loh@URMC.Rochester.edu
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- Recruiting
- University of Rochester
-
Contact:
- Kah Poh Loh
- Phone Number: 585-276-4353
- Email: Kahpoh_Loh@URMC.Rochester.edu
-
Principal Investigator:
- Kah Poh Loh
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Description
Patient
Inclusion Criteria:
- Age ≥65 years
- A diagnosis of cancer
- Planning to initiate or during first three months of oral anticancer treatments
- Able to identify at least one network member to participate with them
- Able to speak English
- Able to provide informed consent
Exclusion Criteria:
- Any psychiatric or cognitive impairments interfering with participation as determined by the treating oncology team
- Enrolled on oral anticancer therapeutic trials
Network Members:
Inclusion Criteria:
- Age ≥18 years
- Identified as a network member by subjects enrolled on the study (up to 10 network members)
- Able to speak English.
- Able to provide informed consent
Exclusion Criteria:
None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 - SONATA Intervention
|
The SONATA intervention is composed of five components, network diagnostics, network engagement, opportunity creation, skill building and goal-setting, and feedback, that will be audio-recorded and held over six scheduled sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility - SONATA Intervention
Time Frame: 20 Weeks
|
Number of patients approached who consent
|
20 Weeks
|
Acceptability- SONATA Intervention
Time Frame: 20 Weeks
|
Average general acceptability score using the Theoretical Framework of Acceptability questionnaire.
An eight item (range 1 to 5 for each item) psychometrically validated and theoretically informed tool which assesses the following constructs - affective attitude, burden, ethicality, perceived effectiveness, intervention coherence, self-efficacy, opportunity costs, and general acceptability.
|
20 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimate - Trust in Healthcare Professionals
Time Frame: 20 Weeks
|
Assessed using the the Human Connection (THC) Scale.
The THC scale is A 16-item scale (range 1 to 4 for each item); higher scores indicate greater trust.
|
20 Weeks
|
Estimate - Adherence to oral anticancer treatments
Time Frame: 20 Weeks
|
Assessed using the Domains of Subjective Extent of Nonadherence (DOSE-Nonadherence).
The DOSE-Nonadherence scale is a three-item scale (range from none of the time to every time for each item) with eighteen additional items that assesses reasons for non-adherence.
|
20 Weeks
|
Estimate - Social Support
Time Frame: 20 Weeks
|
Assessed using the Medical Outcomes Study Social Support Survey.
The Medical Outcomes Study Social Support Survey is a 19-item survey (range 1-5 for each item) to assess four domains of emotional/informational support, instrumental support, positive social interaction, and affection; higher scores indicate greater social support.
Subjects will be asked about their perceptions of their own social support.
|
20 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 29, 2023
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
February 15, 2023
First Submitted That Met QC Criteria
February 15, 2023
First Posted (Actual)
February 27, 2023
Study Record Updates
Last Update Posted (Actual)
March 7, 2024
Last Update Submitted That Met QC Criteria
March 5, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UOCPC22065
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Study protocol and dataset will be shared upon request from the PI
IPD Sharing Time Frame
The data will be available for 7 years from accrual of the first subject.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on SONATA
-
GynesonicsCompletedUterine Fibroids | AdhesionsUnited Kingdom, Germany, Netherlands, Switzerland
-
GynesonicsCompletedMenorrhagiaUnited States, Mexico
-
Roxane LaboratoriesCompletedShort Term Treatment of InsomniaUnited States
-
Medical University of South CarolinaTerminatedEpilepsy | Seizures | Photoparoxysmal AbnormalitiesUnited States
-
Teva Pharmaceuticals USACompleted
-
GynesonicsRecruitingUterine FibroidGermany, Switzerland, United Kingdom
-
Teva Pharmaceuticals USACompleted
-
CHU de Quebec-Universite LavalCompletedSurgical PerformanceCanada
-
St. Luke's Hospital, Chesterfield, MissouriAmerican Academy of Sleep MedicineCompletedSleep | MemoryUnited States